Landos Biopharma, Inc. Common Stock
LABP
LABP was delisted on the 23rd of May, 2024.
10 hedge funds and large institutions have $5.58M invested in Landos Biopharma, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.
6% less capital invested
Capital invested by funds: $5.93M → $5.58M (-$341K)
9% less funds holding
Funds holding: 11 → 10 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$3.94K |
| 2 |
CPG
Cornerstone Planning Group
Fairfield,
New Jersey
|
+$47 |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$20 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.58K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
1
Perceptive Advisors
New York
| $5.44M | – | – | – |
|
2
Macquarie Group
Sydney, NSW 2000,
Australia
| $54K | – | – | – |
|
3
Geode Capital Management
Boston,
Massachusetts
| $46.1K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $41K | +$3.94K | +1,000 | +10% |
|
5
JP Morgan Chase
New York
| $216 | – | – | – |
|
6
BlackRock
New York
| $154 | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $154 | +$20 | +5 | +14% |
|
|
CPG
8
Cornerstone Planning Group
Fairfield,
New Jersey
| $44 | +$47 | +12 | New |
|
|
9
Wells Fargo
San Francisco,
California
| $37 | +$4 | +1 | +11% |
|
|
10
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$5K | -1,209 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$4.58K | -1,180 | Closed |
|
LABP Hedge Fund Activity: Q4 2023 in Review
10 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q4 2023, worth a combined $5.58M — down 5.8% from $5.93M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LABP and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $3.94K. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $5K sold.
- 10 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q4 2023, down from 11 in Q3 2023.
- Funds reported $5.58M of Landos Biopharma, Inc. Common Stock stock for Q4 2023, down 5.8% quarter-over-quarter.
- 1 fund opened new Landos Biopharma, Inc. Common Stock positions in Q4 2023 and 2 closed out, a net change of -1 holder.
- The largest Landos Biopharma, Inc. Common Stock buyer in Q4 2023 was Renaissance Technologies, an estimated $3.94K added.
- The largest Landos Biopharma, Inc. Common Stock seller in Q4 2023 was Royal Bank of Canada, an estimated $5K sold.
Based on aggregated 13F filings for Q4 2023.